Evaluation of Safety and Immunogenicity of Co-administering HPV Vaccine With Other Vaccines in Healthy Female Subjects

PHASE3CompletedINTERVENTIONAL
Enrollment

1,330

Participants

Timeline

Start Date

September 26, 2006

Primary Completion Date

November 22, 2007

Study Completion Date

February 13, 2008

Conditions
Infections, Papillomavirus
Interventions
BIOLOGICAL

Different formulations of GSK Biologicals' HPV vaccine (580299)

Three doses of vaccine administered intramuscularly, with the second and third dose given one month and six months after the first dose respectively

BIOLOGICAL

Menactra TM

One dose of vaccine administered intramuscularly

BIOLOGICAL

Boostrix TM

One dose of vaccine administered intramuscularly

Trial Locations (50)

14620

GSK Investigational Site, Rochester

15220

GSK Investigational Site, Pittsburgh

15401

GSK Investigational Site, Uniontown

16125

GSK Investigational Site, Greenville

16501

GSK Investigational Site, Erie

19107

GSK Investigational Site, Philadelphia

22015

GSK Investigational Site, Burke

22180

GSK Investigational Site, Vienna

27518

GSK Investigational Site, Cary

27609

GSK Investigational Site, Raleigh

28352

GSK Investigational Site, Laurinburg

28779

GSK Investigational Site, Sylva

29401

GSK Investigational Site, Charleston

29407

GSK Investigational Site, Charleston

30062

GSK Investigational Site, Marietta

32931

GSK Investigational Site, Cocoa Beach

33409

GSK Investigational Site, West Palm Beach

36608

GSK Investigational Site, Mobile

37615

GSK Investigational Site, Gray

40004

GSK Investigational Site, Bardstown

40202

GSK Investigational Site, Louisville

40503

GSK Investigational Site, Lexington

44118

GSK Investigational Site, Cleveland

44308

GSK Investigational Site, Akron

44512

GSK Investigational Site, Boardman

49120

GSK Investigational Site, Niles

49127

GSK Investigational Site, Stevensville

66219

GSK Investigational Site, Lenexa

67005

GSK Investigational Site, Arkansas City

67207

GSK Investigational Site, Wichita

68134

GSK Investigational Site, Omaha

71111

GSK Investigational Site, Bossier City

72205

GSK Investigational Site, Little Rock

72401

GSK Investigational Site, Jonesboro

76904

GSK Investigational Site, San Angelo

80112

GSK Investigational Site, Centennial

80233

GSK Investigational Site, Thornton

80401

GSK Investigational Site, Golden

85203

GSK Investigational Site, Mesa

85224

GSK Investigational Site, Chandler

87131

GSK Investigational Site, Albuquerque

90274

GSK Investigational Site, Rolling Hills Estates

90806

GSK Investigational Site, Long Beach

92708

GSK Investigational Site, Fountain Valley

93637

GSK Investigational Site, Madera

93720

GSK Investigational Site, Fresno

97216

GSK Investigational Site, Portland

01757

GSK Investigational Site, Milford

08817

GSK Investigational Site, Edison

08889

GSK Investigational Site, Whitehouse Station

Sponsors

Lead Sponsor

All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT00369824 - Evaluation of Safety and Immunogenicity of Co-administering HPV Vaccine With Other Vaccines in Healthy Female Subjects | Biotech Hunter | Biotech Hunter